Cypherpunk Technologies Inc. (CYPH)
NASDAQ: CYPH · Real-Time Price · USD
1.285
-0.025 (-1.91%)
At close: Dec 4, 2025, 4:00 PM EST
1.290
+0.005 (0.39%)
After-hours: Dec 4, 2025, 7:59 PM EST
Cypherpunk Technologies Employees
Cypherpunk Technologies had 52 employees as of December 31, 2024. The number of employees decreased by 2 or -3.70% compared to the previous year.
Employees
52
Change (1Y)
-2
Growth (1Y)
-3.70%
Revenue / Employee
n/a
Profits / Employee
-$981,654
Market Cap
72.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | -2 | -3.70% |
| Dec 31, 2023 | 54 | 10 | 22.73% |
| Dec 31, 2022 | 44 | 8 | 22.22% |
| Dec 31, 2021 | 36 | 6 | 20.00% |
| Dec 31, 2020 | 30 | 4 | 15.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Berkshire Hathaway | 392,400 |
| JPMorgan Chase & Co. | 317,233 |
| Wells Fargo & Company | 217,000 |
| Bank of America | 213,000 |
| HSBC Holdings | 211,304 |
| Royal Bank of Canada | 91,427 |
| Morgan Stanley | 80,000 |
| American Express Company | 75,100 |
CYPH News
- 22 days ago - Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results - PRNewsWire
- 22 days ago - Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy - PRNewsWire
- 6 weeks ago - Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 - PRNewsWire
- 2 months ago - Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 2 months ago - Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 2 months ago - Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 - PRNewsWire
- 4 months ago - Leap Therapeutics Reports Second Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives - PRNewsWire